IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26776758.
- Also identified by DOI 10.1016/j.pcd.2015.12.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In type 2 diabetes (T2D), treatment is optimised to minimise hyperglycaemia and the risk of microvascular complications. While there are a number of effective treatments, intensive treatment is associated with negative side effects such as increased hypoglycaemia and weight gain. With complementary modes of action, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and a basal insulin in combination offer an alternative to basal-bolus therapy in T2D. This review describes the rationale behind this treatment combination and presents clinical data available for IDegLira, the first basal insulin (insulin degludec) and GLP-1RA (liraglutide) co-formulation available in one pen for a single injection daily.
Medical subject headings
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Incretins
- Insulin, Long-Acting
- Liraglutide